PDRX Stock Overview
PD-Rx Pharmaceuticals, Inc. engages in the repackaging and distribution of prepackaged pharmaceutical products for the healthcare industry in the United States.
PD-Rx Pharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$3.15|
|52 Week High||US$3.15|
|52 Week Low||US$2.00|
|1 Month Change||5.00%|
|3 Month Change||n/a|
|1 Year Change||12.70%|
|3 Year Change||-30.00%|
|5 Year Change||-46.15%|
|Change since IPO||110.00%|
Recent News & Updates
|PDRX||US Healthcare||US Market|
Return vs Industry: PDRX exceeded the US Healthcare industry which returned 1.2% over the past year.
Return vs Market: PDRX exceeded the US Market which returned -20.8% over the past year.
|PDRX Average Weekly Movement||n/a|
|Healthcare Industry Average Movement||9.3%|
|Market Average Movement||7.9%|
|10% most volatile stocks in US Market||16.5%|
|10% least volatile stocks in US Market||3.1%|
Stable Share Price: Insufficient data to determine PDRX's volatility over the past 3 months.
Volatility Over Time: Insufficient data to determine PDRX's volatility change over the past year.
About the Company
PD-Rx Pharmaceuticals, Inc. engages in the repackaging and distribution of prepackaged pharmaceutical products for the healthcare industry in the United States. The company provides approximately 2,600 prepackaged medications; and creams, ointments, ophthalmics, otics, liquids, suspensions, etc. It also offers PD-Rx Net, a web-based application that tracks prescriptions filled at the point of care and print prescription labels for prescription that filled onsite; and manual dispensing system that provides 10 recordkeeping labels to match the 10 bottle trays as a convenient handling package for physician dispensing customers. In addition, the company provides professional assistance by staffed pharmacists and physicians; and pharmaceutical sampling program design to reduce MCO’s pharmaceutical costs, as well as allows medical professionals to offer pre-filled prescriptions to patients free of charge.
PD-Rx Pharmaceuticals Fundamentals Summary
|PDRX fundamental statistics|
Is PDRX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PDRX income statement (TTM)|
|Cost of Revenue||US$14.65m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||1.13|
|Net Profit Margin||8.59%|
How did PDRX perform over the long term?See historical performance and comparison
Is PDRX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for PDRX?
Other financial metrics that can be useful for relative valuation.
|What is PDRX's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does PDRX's PE Ratio compare to its peers?
|PDRX PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
Price-To-Earnings vs Peers: PDRX is good value based on its Price-To-Earnings Ratio (2.8x) compared to the peer average (15.5x).
Price to Earnings Ratio vs Industry
How does PDRX's PE Ratio compare vs other companies in the U.S. Healthcare Industry?
Price-To-Earnings vs Industry: PDRX is good value based on its Price-To-Earnings Ratio (2.8x) compared to the US Healthcare industry average (18.4x)
Price to Earnings Ratio vs Fair Ratio
What is PDRX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||2.8x|
|Fair PE Ratio||n/a|
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate PDRX's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of PDRX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate PDRX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate PDRX's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PDRX's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is PD-Rx Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as PD-Rx Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine PD-Rx Pharmaceuticals's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access PD-Rx Pharmaceuticals's filings and announcements here.
How has PD-Rx Pharmaceuticals performed over the past 5 years?
Past Performance Score3/6
Past Performance Score 3/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PDRX has a high level of non-cash earnings.
Growing Profit Margin: PDRX became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: PDRX's earnings have grown by 13.2% per year over the past 5 years.
Accelerating Growth: PDRX has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: PDRX has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare industry (9.5%).
Return on Equity
High ROE: PDRX's Return on Equity (21.9%) is considered high.
Discover strong past performing companies
How is PD-Rx Pharmaceuticals's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: PDRX's short term assets ($10.0M) exceed its short term liabilities ($2.4M).
Long Term Liabilities: PDRX has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: PDRX is debt free.
Reducing Debt: PDRX had no debt 5 years ago.
Debt Coverage: PDRX has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: PDRX has no debt, therefore coverage of interest payments is not a concern.
Discover healthy companies
What is PD-Rx Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PDRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PDRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PDRX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PDRX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as PDRX has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Robert Holsey (68 yo)
Dr. Robert D. Holsey D.O., R.Ph. has been a Director of Pd-rx Pharmaceuticals Inc. since 1986 and serves as President, Chief Executive Officer and Chairman of the Board and a practicing physician. Dr. Hols...
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
PD-Rx Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources
- Name: PD-Rx Pharmaceuticals, Inc.
- Ticker: PDRX
- Exchange: OTCPK
- Founded: 1986
- Industry: Health Care Distributors
- Sector: Healthcare
- Implied Market Cap: US$5.182m
- Shares outstanding: 1.65m
- Website: https://www.pdrx.com
- PD-Rx Pharmaceuticals, Inc.
- 727 North Ann Arbor
- Oklahoma City
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/23 00:00|
|End of Day Share Price||2022/05/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.